Stockscreener 앱 받기
1.65
0.60%
-0.01
시간 외 거래:
1.65
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2025 Earnings Call Transcript - Insider Monkey
Inovio stock up on earnings, pipeline progress - MSN
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INO DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors ... - Bluefield Daily Telegraph
INO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) ... - Bluefield Daily Telegraph
LEVI & KORSINSKY, LLP: APRIL 7, 2026 -- DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION - PR Newswire
Equities Analysts Set Expectations for INO Q1 Earnings - MarketBeat
INOVIO to Present DNA Medicine Data at Two Scientific Conferences - MyChesCo
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - PR Newswire
Inovio (INO) Q4 2025 Earnings Call Transcript - The Globe and Mail
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 (2026-03-17) - Seeking Alpha
Holzer & Holzer, LLC Reminds Investors of April 7, 2026 - GlobeNewswire
Inovio Pharmaceuticals Q4 2025 earnings preview - MSN
DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law - GlobeNewswire
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Levi & Korsinsky, LLP: CEO and CFO Named as Control Person Defendants in Inovio Pharmaceuticals Securities Action - GlobeNewswire
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Investors Urged to Join Securities Fraud Lawsuit - National Today
Bronstein, Gewirtz & Grossman LLC Urges Inovio - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors - GlobeNewswire
INOVIO Pharmaceuticals spotlights INO-3107 potential in HPV-related cancer treatment at Eurogin - Traders Union
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Layoff Tracker: Inovio Slims Down as Lead Asset Nears Market - BioSpace
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Inovio - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure ... - Caledonian Record
Boxer Capital Management LLC Purchases New Shares in Inovio Pharmaceuticals, Inc. $INO - MarketBeat
Inovio Stock Up On Earnings, Pipeline Progress - Sahm
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at Wall Street Zen - MarketBeat
INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio cut 16% of workforce over the past year as FDA decision looms on drug application - The Business Journals
Inovio Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:INO) 2026-03-13 - Seeking Alpha
User - The Chronicle-Journal
INO Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Inovio Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Inovio Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Sahm
INO Stock Price, Quote & Chart | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill
Inovio: Q4 Earnings Snapshot - theheraldreview.com
Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlight - GuruFocus
Inovio Pharmaceuticals (INO) Advances BLA Review for INO-3107 - GuruFocus
Inovio Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
INO: INO-3107 BLA under FDA review; cash runway extended into Q4 2026 amid focused pipeline progress - TradingView
Earnings call transcript: Inovio Pharmaceuticals’ Q4 2025 results highlight cost reductions - Investing.com
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Resul - GuruFocus
Inovio Pharmaceuticals (NASDAQ:INO) Issues Quarterly Earnings Results, Beats Estimates By $0.68 EPS - MarketBeat
Inovio Q4 Profit Surprise: 31 Cents EPS Against Forecasted Loss | 2026News and Statistics - IndexBox
Inovio: Fourth Quarter Earnings Overview - Bitget
INO Advances INO-3107 Amid Financial Adjustments - GuruFocus
Inovio, Akeso partner on Phase 2 trial of new immunotherapy for glioblastoma - Rare Cancer News
1.20%
0.06%
자본화:
|
볼륨(24시간):